Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 2;23(19):11693.
doi: 10.3390/ijms231911693.

Impact of Acetate versus Citrate Dialysates on Intermediary Metabolism-A Targeted Metabolomics Approach

Affiliations

Impact of Acetate versus Citrate Dialysates on Intermediary Metabolism-A Targeted Metabolomics Approach

José Jesús Broseta et al. Int J Mol Sci. .

Abstract

Acetate is widely used as a dialysate buffer to avoid the precipitation of bicarbonate salts. However, even at low concentrations that wouldn't surpass the metabolic capacity of the Krebs tricarboxylic acid (TCA) cycle, other metabolic routes are activated, leading to undesirable clinical consequences by poorly understood mechanisms. This study aims to add information that could biologically explain the clinical improvements found in patients using citrate dialysate. A unicentric, cross-over, prospective targeted metabolomics study was designed to analyze the differences between two dialysates, one containing 4 mmol/L of acetate (AD) and the other 1 mmol/L of citrate (CD). Fifteen metabolites were studied to investigate changes induced in the TCA cycle, glycolysis, anaerobic metabolism, ketone bodies, and triglyceride and aminoacidic metabolism. Twenty-one patients completed the study. Citrate increased during the dialysis sessions when CD was used, without surpassing normal values. Other differences found in the next TCA cycle steps showed an increased substrate accumulation when using AD. While lactate decreased, pyruvate remained stable, and ketogenesis was boosted during dialysis. Acetylcarnitine and myo-inositol were reduced during dialysis, while glycerol remained constant. Lastly, glutamate and glutarate decreased due to the inhibition of amino acidic degradation. This study raises new hypotheses that need further investigation to understand better the biochemical processes that dialysis and the different dialysate buffers induce in the patient's metabolism.

Keywords: acetate; acetate-free; citrate; dialysate; hemodialysis; targeted metabolomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Heat map representing the normalized data by Z-scoring of each metabolite in the four measurement times. It is clear that dialysis per se has a catabolic effect and that most of the differences are produced by the treatment; however, it is visible that, in some cases, the metabolite concentrations are very disparate between dialysates.
Figure 2
Figure 2
Violin plot representing the pre- and post-dialysis measured concentrations of the fifteen studied metabolites with each dialysate. Statistically significant differences are marked.

References

    1. Stegmayr B. Dialysis Procedures Alter Metabolic Conditions. Nutrients. 2017;9:548. doi: 10.3390/nu9060548. - DOI - PMC - PubMed
    1. Hocher B., Adamski J. Metabolomics for clinical use and research in chronic kidney disease. [(accessed on 7 August 2021)];Nat. Rev. Nephrol. 2017 13:269–284. doi: 10.1038/nrneph.2017.30. Available online: https://pubmed.ncbi.nlm.nih.gov/28262773/ - DOI - PubMed
    1. Zhu S., Zhang F., Shen A.-W., Sun B., Xia T.-Y., Chen W.-S., Tao X., Yu S.-Q. Metabolomics Evaluation of Patients with Stage 5 Chronic Kidney Disease before Dialysis, Maintenance Hemodialysis, and Peritoneal Dialysis. [(accessed on 7 August 2021)];Front. Physiol. 2021 11:630646. doi: 10.3389/fphys.2020.630646. Available online: https://pubmed.ncbi.nlm.nih.gov/33551851/ - DOI - PMC - PubMed
    1. Kalantari S., Nafar M. An update of urine and blood metabolomics in chronic kidney disease. [(accessed on 7 August 2021)];Biomark. Med. 2019 13:577–597. doi: 10.2217/bmm-2019-0008. Available online: https://pubmed.ncbi.nlm.nih.gov/31140832/ - DOI - PubMed
    1. Tamura M.K., Chertow G.M., Depner T.A., Nissenson A.R., Schiller B., Mehta R.L., Liu S., Sirich T.L. Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis. [(accessed on 7 August 2021)];J. Am. Soc. Nephrol. 2016 27:3780–3787. doi: 10.1681/ASN.2016010039. Available online: https://pubmed.ncbi.nlm.nih.gov/27444566/ - DOI - PMC - PubMed

LinkOut - more resources